Varenka Rodriguez DiBlasi, Exploratory Bioinformatics Lab Head of Cancer Immunology at Boehringer Ingelheim, shared a case study at D4 USA last October, with some of the computational approaches her team use to identify novel target leads, and the multi-omics study design they use to validate them.
Dr Diblasi covered the following in the slides she has shared below:
- Quantifying tumour immune and stroma contexture with transcriptome and chromatin landscapes
- Challenges in integrating these datasets into a harmonized atlas that can be used to better understand cellular identity and function
- Cell signatures redefined by multi-omics approaches
- TME Spatial Features
